Thyroid Dysfunction Induced by Anti-PD-1 Therapy in Patients With Advanced Carcinoma
NCT ID: NCT05593744
Last Updated: 2022-10-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2020-08-17
2022-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
No Prognostic or Molecular Disparity Between Synchronous and Metachronous Metastases in Differentiated Thyroid Cancer: Insight From Middle Eastern Cohort
NCT07115810
Metastatic Thyroid Cancer Therapy Optimization With 124I PET Dosimetry
NCT05299437
The Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China
NCT04857086
Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused by Thyroidectomy in Thyroid Cancer Patients.
NCT05247476
Impact of Conventional Treatments and Clinical Variables on Thyroid Cancer
NCT05752604
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Thyroid dysfunction
Patients had thyroid dysfunction during anti-PD-1 therapy.
no intervention
This is an observational study so not involved intervention
No thyroid dysfunction
Patients didn't have thyroid dysfunction during anti-PD-1 therapy.
no intervention
This is an observational study so not involved intervention
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
no intervention
This is an observational study so not involved intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed diagnosis of malignancy
* Received anti-PD-1 therapy
Exclusion Criteria
* Thyroid dysfunction before anti-PD-1 therapies
* Previous ICIs treatment
* Less than 2 cycles of anti-PD-1 treatment
* No thyroid function monitoring during treatment
* Known pituitary disease
* Pregnancy.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Qilu Hospital of Shandong University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Qilu Hospital, Shandong University
Jinan, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lu Y, Li Q, Xu L, Zheng Y, Wang Y, Liu Y, Zhang R, Liao L, Dong J. Thyroid dysfunction induced by anti-PD-1 therapy is associated with a better progression-free survival in patients with advanced carcinoma. J Cancer Res Clin Oncol. 2023 Dec;149(18):16501-16510. doi: 10.1007/s00432-023-05364-z. Epub 2023 Sep 15.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SDU-KYLL-202208-042
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.